Howland Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Howland Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36M	Buy	4,534 +300	+7%	+$90.5K	0.05%	143
2026 Q1	$1.4M	Sell	4,234 -9	-0.2%	-$3.06K	0.06%	135
2025 Q4	$1.69M	Hold	4,243	–	–	0.06%	122
2025 Q3	$1.93M	Buy	4,243 +243	+6%	+$99K	0.07%	120
2025 Q2	$1.3M	Hold	4,000	–	–	0.05%	139
2025 Q1	$1.08M	Hold	4,000	–	–	0.05%	146
2024 Q4	$941K	Hold	4,000	–	–	0.04%	150
2024 Q3	$1.1M	Hold	4,000	–	–	0.05%	144
2024 Q2	$972K	Hold	4,000	–	–	0.05%	140
2024 Q1	$598K	Hold	4,000	–	–	0.03%	173
2023 Q4	$766K	Buy	+4,000	New	+$681K	0.04%	150
2023 Q3	–	Sell	-4,000	Closed	-$760K	–	246
2023 Q2	$760K	Hold	4,000	–	–	0.04%	149
2023 Q1	$801K	Hold	4,000	–	–	0.05%	142
2022 Q4	$951K	Hold	4,000	–	–	0.06%	130
2022 Q3	$801K	Buy	+4,000	New	+$763K	0.05%	132

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Howland Capital Management's ALNY Position: Q2 2026 in Review

Howland Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 7.1% in Q2 2026, buying an estimated $90.5K and bringing the position to 4,534 shares worth $1.36M. The position accounts for 0.05% of the portfolio, ranked #143.

Howland Capital Management first reported a position in ALNY in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.93M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Howland Capital Management held 4,534 shares of Alnylam Pharmaceuticals worth $1.36M as of Q2 2026.
Howland Capital Management bought 300 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $90.5K.
Alnylam Pharmaceuticals made up 0.05% of Howland Capital Management's portfolio in Q2 2026, its #143 holding.
Howland Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Howland Capital Management's Alnylam Pharmaceuticals position peaked at $1.93M in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Howland Capital Management's 13F filing for Q2 2026, filed 13 Jul 2026.